Supply Chain Intelligence

Autolus Therapeutics plc Supply Chain

AUTL supply chain intelligence for Autolus Therapeutics plc: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

AUTL ·Last updated 2026-07-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

3Suppliers
3Customers
1Debt Items
20Related Chains

Autolus Therapeutics plc Suppliers

TickerNameConfidenceEvidence
AGC-BIOLOGICS-S-P-A AGC-BIOLOGICS-S-P-A 92% The Agreement replaces and supersedes the prior arrangement between the Company and AGC, pursuant to which AGC has provided similar products and services.
CONTRACT-RESEARCH-ORGANIZATION CONTRACT-RESEARCH-ORGANIZATION 85% Qualifying expenditures largely comprise of employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects…
LEGN Legend Biotech Corporation 72% Reciprocal relationship from LEGN graph: Reciprocal relationship from AUTL graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from AUTL graph: Reciprocal relationship from LEGN g…

Autolus Therapeutics plc Customers

TickerNameConfidenceEvidence
NATIONAL-HEALTH-SERVICE NATIONAL-HEALTH-SERVICE 90% AUCATZYL is available through the National Health Service ("NHS") and private treatment centers.
LEGN Legend Biotech Corporation 72% Reciprocal relationship from LEGN graph: ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, i…
TCRX TScan Therapeutics, Inc. 72% Reciprocal relationship from TCRX graph: Reciprocal relationship from AUTL graph: Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver…

Autolus Therapeutics plc Debt Obligations

InstrumentDescriptionConfidenceEvidence
AUTL-DEBT-7986 Warrants outstanding: 7.35 90% xbrl warrant detail from xbrl 2021-12-31.

Autolus Therapeutics plc Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Autolus Therapeutics plc.

Autolus Therapeutics plc Ownership

HolderNameConfidenceEvidence
AUTL-OWNER-MAK-CAPITAL-ONE-LLC MAK CAPITAL ONE LLC 90% 13F overlay lists MAK CAPITAL ONE LLC as top holder; 84 tracked holders.

Autolus Therapeutics plc Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
MGNX MacroGenics, Inc. 100.00 2
JNJ Johnson & Johnson 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
RNAC Cartesian Therapeutics, Inc. 100.00 2
ROIV Roivant Sciences Ltd. 100.00 2
BCAX Bicara Therapeutics Inc. 100.00 2
IOVA Iovance Biotherapeutics, Inc. 100.00 2
NVSEF Novartis AG 100.00 2
NTLA Intellia Therapeutics, Inc. 100.00 2
LYEL Lyell Immunopharma, Inc. 100.00 2
LEGN Legend Biotech Corporation 100.00 1 ['customer', 'supplier']
DTIL Precision BioSciences, Inc. 100.00 2
BMY Bristol-Myers Squibb Company 100.00 2
BMYMP Bristol-Myers Squibb Co 100.00 2
KYTX Kyverna Therapeutics, Inc. 100.00 2
GSK GSK plc 100.00 2
IPSC Century Therapeutics, Inc. 100.00 2
TKPHF Takeda Pharmaceutical Company Limited 100.00 2
View AUTL supply chain intel →

Explore the full interactive supply chain map for Autolus Therapeutics plc.

Open AUTL supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map